ALC vs ORKA
Alcon Inc vs Oruka Therapeutics, Inc. — AI-powered side-by-side comparison
VS
ORKA
Oruka Therapeutics, Inc.
59
Watch
| Metric | ALC | ORKA |
|---|
| AI Score |
68
|
59
|
| Price |
$75.39
|
$104.56
|
| P/E Ratio |
45.39×
|
-43.80×
|
| ROE |
4.4%
|
-22.3%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
54.9%
|
0.0%
|
| Debt / Equity |
0.24×
|
0.00×
|
| Dividend Yield |
0.5%
|
0.0%
|
| RSI (14) |
73.4
|
74.0
|
| Beta |
0.703
|
-0.389
|
| Expected Upside |
+11.3%
|
—
|
AI Committee View
Current Innellis committee reasoning for ALC versus ORKA.
ALC leads by 9 points.
ALC scores 68/100 (Buy) versus ORKA at 59/100 (Watch).
ALC Committee View
75% agreement
4 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. The main limiting factor is rsi at 73 is in overbought territory. The committee is constructive but not yet at full conviction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- RSI at 73 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
ORKA Committee View
60% agreement
5 analysts
Some positive signals exist — vix regime is low -- calm backdrop supports risk-taking — but they are not yet strong enough to justify a Buy. The committee is monitoring for confirmation.
Bull Case
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- ROE of only -26.0% -- cheap may mean cheap for a reason — Value
- RSI at 74 is in overbought territory — Technical
- Weekly RSI at 86 -- overbought on the larger timeframe too — Technical